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Background: There is a pressing need in rheumatoid arthritis (RA) to identify patients who will not respond to first-
line disease-modifying anti-rheumatic drugs (DMARD). We explored whether differences in genomic architecture 
represented by a chromosome conformation signature (CCS) in blood taken from early RA patients before methotrex-
ate (MTX) treatment could assist in identifying non-response to DMARD and, whether there is an association between 
such a signature and RA specific expression quantitative trait loci (eQTL).
Methods: We looked for the presence of a CCS in blood from early RA patients commencing MTX using chro-
mosome conformation capture by EpiSwitch™. Using blood samples from MTX responders, non-responders and 
healthy controls, a custom designed biomarker discovery array was refined to a 5-marker CCS that could discriminate 
between responders and non-responders to MTX. We cross-validated the predictive power of the CCS by generating 
150 randomized groups of 59 early RA patients (30 responders and 29 non-responders) before MTX treatment. The 
CCS was validated using a blinded, independent cohort of 19 early RA patients (9 responders and 10 non-responders). 
Last, the loci of the CCS markers were mapped to RA-specific eQTL.
Results: We identified a 5-marker CCS that could identify, at baseline, responders and non-responders to MTX. The 
CCS consisted of binary chromosome conformations in the genomic regions of IFNAR1, IL-21R, IL-23, CXCL13 and 
IL-17A. When tested on a cohort of 59 RA patients, the CCS provided a negative predictive value of 90.0% for MTX 
response. When tested on a blinded independent validation cohort of 19 early RA patients, the signature demon-
strated a true negative response rate of 86 and a 90% sensitivity for detection of non-responders to MTX. Only confor-
mations in responders mapped to RA-specific eQTL.
Conclusions: Here we demonstrate that detection of a CCS in blood in early RA is able to predict inadequate 
response to MTX with a high degree of accuracy. Our results provide a proof of principle that a priori stratification 
of response to MTX is possible, offering a mechanism to provide alternative treatments for non-responders to MTX 
earlier in the course of the disease.
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Background
Rheumatoid arthritis (RA) is an autoimmune inflam-
matory disorder driven by interacting genetic, epige-
netic and environmental factors [1–3]. The diagnosis 
of RA prompts early initiation of methotrexate (MTX), 
the first choice of disease modifying anti-rheumatic 
drug (DMARD) as recommended by European League 
against Rheumatism (EULAR) and American College 
of Rheumatology (ACR) ‘treat-to-target’ strategy (target 
being remission or low disease activity). This approach 
has substantially improved outcomes in the last decade 
[4–6]. However, approximately 35–59% of patients do 
not achieve clinically meaningful responses after start-
ing MTX [7]. Predicting response to MTX has been 
one of the main challenges in RA management for over 
two decades [8]. Delay of effective treatment has clini-
cal implications as response to MTX is the most signifi-
cant predictor of long-term outcome in RA [9–11]. The 
ability to identify biomarkers able to predict inadequate 
response has thus far proven challenging [7, 12–15]. 
Several attempts have been made to develop diagnostics 
able to predict MTX-response [16–23] (Additional file 1: 
Table S1) however, most studies have failed.
RA is dependent on the interaction of genetic and envi-
ronmental factors [24, 25]. Epigenetic markers are closely 
linked to transcriptional regulation and may reflect path-
ogenic changes associated with disease states [26–30]. 
The first evidence suggesting that epigenetic mechanisms 
may play a role in autoimmune diseases came from stud-
ies performed by Richardson et  al. looking at the effect 
of DNA methyltransferase inhibitor 5-azacytidine [31]. 
Other studies have also reported aberrant methylation 
in RA [32–38]. Interestingly, MTX treatment also plays 
a role in epigenetic regulation in RA [39–41]. Gene 
expression in mammals is regulated by non-coding ele-
ments that can impact physiology and disease; the 
principle mechanism of regulation is through the archi-
tectural status at both coding and non-coding genomic 
regions [26]. Under external perturbations, genomic 
regions can alter their 3-dimensional structure as a way 
of functional regulation of gene expression [42]. These 
structural changes can be measured by EpiSwitch, a high-
throughput molecular technique that analyzes the spatial 
organization of genomic loci in a cell [43–45]. As mul-
tiple genomic regions contribute to phenotypic differ-
ences through changes in genomic architecture [26], this 
approach allows for the development of a chromosomal 
conformation signature (CCS) of alterations in genomic 
architecture between two states (disease vs. non-disease, 
pre-treatment vs. post-treatment). The evaluation of 
long range chromosome interactions has provided use-
ful blood-based biomarkers in oncology and other non-
rheumatic diseases [44–48]. CCS offer a stable, binary 
readout of cellular states and represent an emerging class 
of biomarkers [49]. Here, we used a chromosomal archi-
tecture based approach to predict the response to MTX 
by developing a blood-based classifier based on a CCS. 
We hypothesized that interrogation of genomic architec-
tural changes in early RA patients would define a func-
tional endotype able to guide clinical decision making.
Methods
Patient population
The SERA study is a national prospective inception 
cohort of patients with new RA or undifferentiated 
arthritis, together with age-gender matched controls 
[50, 51]. We used 67 SERA patients for the discovery/
validation phases (plus 34 healthy controls) and an addi-
tional 19 patients from an independent cohort, who were 
enrolled in a blinded validation study (demographic and 
clinical characteristics are shown in Additional file  1: 
Tables S2–S4). Participants fulfilled the 2010 ACR/
EULAR RA criteria at recruitment and commenced mon-
otherapy with MTX. Importantly, patients were treated 
to standard of care according to SIGN Guidelines (http://
www.sign.ac.uk/pdf/sign123.pdf) reflecting the true to 
life, population wide cohort design of SERA. Patients 
were treated with standard therapy, which included intra-
articular or intra-muscular glucocorticoids, offered as 
required in the absence of low dose oral glucocorticoids. 
Clinical data to calculate a range of composite clinical 
outcomes were obtained at baseline and after 6  months 
of MTX treatment (Additional file 1: Tables S2–S4). DAS 
(Disease Activity Score) response was calculated on the 
basis of either DAS28 (ESR) or DAS28 (CRP) change to 
meet the following criteria for response. Responders 
(R) were defined as those achieving DAS28 remission 
(DAS28 < 2.6) or a good response (DAS28 improvement 
of  >  1.2 and DAS28 ≤  3.2) at 6  months. Non-respond-
ers (NR) were defined as patients who had no improve-
ment in DAS28 (≤ 0.6) by 6 months. For consistency, we 
then calculated a CDAI (Clinical Disease Activity Index) 
response for each patient and used this outcome meas-
ure to ensure comparability of clinical response across 
all patients in the analysis [52, 53]. Baseline peripheral 
blood samples with EDTA were collected and centrifuged 
to generate a buffy layer, stored at − 80 °C. Local ethics 
committees approved the SERA protocol and all partici-
pants gave informed consent before enrollment.
Identification of markers by EpiSwitch™ and probe design
A pattern recognition algorithm was used to annotate 
the human genome for sites with the potential to form 
long-range chromosome conformations. The propri-
etary EpiSwitch pattern recognition software, based on 
Bayesian-modeling, provides a probabilistic score that 
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a region is involved in long-range chromatin interac-
tions [44, 45]. Sequences from 123 gene loci (Additional 
file 1: Table S5), selected based on a systematic literature 
review for genes that have been associated with RA [35, 
54–57], were processed through the pattern recognition 
software to generate a list of the 13,322 chromosomal 
interactions to be screened for association with response 
to MTX in RA. Sixty 60-mer oligonucleotide probes were 
designed to interrogate these potential interactions and 
uploaded as a custom array to the Agilent SureDesign 
website. Importantly, each probe was present in quadru-
plicate on the EpiSwitch™ microarray. To subsequently 
evaluate a potential CCS, nested PCR (EpiSwitch™ PCR) 
was performed using sequence-specific oligonucleotides 
designed using Primer3. Oligonucleotides were tested for 
specificity using oligonucleotide specific BLAST.
Preparation of genomic templates
Chromatin with intact chromosome conformations from 
50 µl of each blood sample was extracted using the EpiS-
witch assay following the manufacturer’s instructions 
(Oxford BioDynamics Ltd.) [43, 45, 46]. The methods 
used to perform an EpiSwitch microarray and EpiSwitch 
PCR detection are described in detail in Supplementary 
Methods.
Statistical analysis
GraphPad Prism and SPSS were used for all statistical 
analyses of clinical data. The R statistical environment 
was used to analyze the CCS data. The Fisher’s exact 
test (for categorical variables), the t test for independent 
samples (for continuous normally distributed variables), 
and the Mann–Whitney U test (for continuous variables 
without normal distribution) were used to identify dif-
ferences. The level of statistical significance was set at 
p ≥ 0.05, and all tests were 2-sided. A full description of 
the statistical methods used to identify the CCS can be 
found in Additional file 1: Additional Methods.
Mapping of CCS locations to expressed quantitative trait 
locus (eQTL)
The genomic locations of the five markers (IFNAR1, 
IL-21R, IL-23, CXCL13 and IL-17A) in the CSS were 
compared with the Walsh et  al. [58] eQTLs data using 
a Window function within the Bedtools suit of genomic 
analysis functions [59]. Only eQTLs that were within 
a genomic window of 100 bp to 2 Kbp were considered 
when mapping to the CCS locations.
Results
Patient characteristics
Demographic and clinical characteristics was captured 
for the early RA patient groups (Stages I, II and III) 
at the time of recruitment and at 6  months following 
MTX therapy (Additional file  1: Table S2–S4). A total 
of 86 early RA patients and 34 healthy controls (HC) 
were included. 67 were used to develop the CCS, and an 
independent, blinded cohort of 19 patients used in vali-
dation (Fig.  1). The biomarker discovery pipeline com-
prised 3 stages (Fig. 1). Stage I, the discovery phase was 
performed using 8 early RA patients (4 MTX-NR and 4 
MTX-R) and 4 HC. Stage II, conducted to test the CCS 
involved 59 early RA patients (30 MTX-NR and 29 MTX-
R) and 30 HC. Stage III validation used an independent, 
blinded cohort of 19 early RA patients (Fig. 1).
Initial definition of the CCS in early RA
To identify an initial set of common epigenetic profiles 
in early RA patients, 123 genetic loci (Additional file  1: 
Table S5) previously associated with RA [35, 54–57] 
were selected and annotated with chromosome confor-
mation interactions predicted using the EpiSwitch in 
silico annotation package [44–46]. The in silico predic-
tion generated 13,322 high-confidence chromosome 
interaction candidates, with an average of 99 per loci 
(99 ± 64; mean ± SD) (Additional file 1: Table S5). These 
candidates were used to generate a bespoke discovery 
CCS array (Additional file  1: Table S5) to screen base-
line whole blood samples from 4 MTX-R and 4 MTX-
NR (Fig.  1; Additional file  1: Table  S2), and 4 HC. Age, 
gender makeup, DAS28, baseline CDAI and MTX doses 
were similar in R and NR patients (Fig. 2a, b; Additional 
file 1: Table S2). We identified 922 statistically significant 
chromosomal interactions that differentiated R, NR and 
HC. Of the 922 lead interactions, 420 were associated 
with NR, 210 with R and 159 with HC. A stepwise hier-
archical clustering approach reduced the number of sig-
nificant interactions from 922 to a 30-marker profile that 
effectively stratified patients (Additional file 1: Figure S1, 
Table S6).
Refinement of the CCS
The 30 interactions identified in the initial screen were 
narrowed to a smaller pool using a second SERA-derived 
early RA patient cohort of 59 patients (30 MTX-R and 
29 MTX-NR) and 30 HCs (Fig.  2c, d; Additional file  1: 
Table S3). Employing a stepwise approach using the EpiS-
witch PCR platform (Additional file  1: Figure S1, blood 
samples from 24 RA patients (12 R and 12 NR) were ana-
lyzed for the interactions that best differentiated between 
R and NR. This resulted in a set of 10 best discrimina-
tory interactions (Additional file 1: Table S6). These ten 
interactions were used to probe blood samples from an 
additional set of 35 RA (18 R and 17 NR). Using logistical 
regression on the combined data from all patients used 
to refine the CCS (that is 30 R and 29 NR), we identified 
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five conformations within the IFNAR1, IL-21R, IL-23, IL-
17A, and CXCL13 loci which provided the final CCS for 
response to MTX (Additional file 1: Figures S2–S6, Table 
S8). The regression coefficients and odds ratio of the 
logistic regression model are shown in Table 1.
The model provided a prediction probability score for 
R and NR, ranging from 0.0098 to 0.99 (0 =  responder, 
1 = non-responder). The cut-off values were set at ≤ 0.30 
for R and ≥ 0.70 for NR. The score of ≤ 0.30 had a true 
positive rate (sensitivity) of 89% (95% confidence inter-
val [95% CI] 72–98%), while a score of  ≥  0.70 had a 
true negative response rate (specificity) of 87% (95% CI 
70–96%). The number of observed and predicted patients 
per response category is shown in Table 2. With the CCS 
classifier, 53 patients (90%) were correctly classified as 
either R or NR.
Testing the performance of the CCS
To test the accuracy and performance robustness of the 
CCS classifier to discriminate non-responders to MTX in 
early RA prior to treatment, data from the 59 early RA 
patient cohort used to develop the classifier was split 
into 150 different training and test sets by random data 
re-sampling using fivefold cross-validation. While this 
analysis was not intended as a true validation since the 
classifier was tested on the same cohort used to develop 
it, this provided an interim measure of the classifiers abil-
ity to discriminate R and NR. The average area under the 
curve (AUC) of the model was 90.6% (95% CI 87–100%), 
with an average sensitivity for NR of 89.7% and an aver-
age specificity for R of 90.0% (Fig. 3a). To determine the 
predictive capability of the CCS classifier, the average 
model accuracy statistics were adjusted for population 
R/NR to MTX [60]. Using a 55% MTX response rate, 
the positive predictive value (PPV) was 88% while the 
negative predictive value (NPV) was 86.4%. When the 
response rate was adjusted to 60%, this decreased the 
PPV to 85.7% while increasing the NPV to 88.6%.
Independent blinded validation
To validate the performance of the CCS, a blinded analy-
sis was undertaken on an additional 19 early RA patients 
from an independent cohort selected from SERA (9 R 
and 10 NR) (Additional file 1: Table S4, Figure S8). This 
validation cohort had similar clinical characteristics 
to those used to develop the CCS with respect to age, 
Fig. 1 Study design. a Samples used for biomarker discovery and validation. A subset of patient samples from the SERA Inception Cohort (86 RA 
patients and 34 HC) were used to discover and validate the MTX response biomarker. b Workflow for discovery and validation of the epigenetic 
stratifying biomarker. For Stage I and Stage II biomarker discovery and testing, clinical samples from MTX-treatment naïve patients were provided 
after confirmation of response by SDAI. In Stage I, an initial panel of 13,322 potential biomarkers was refined to a 5-marker chromosomal conforma-
tion signature (CCS). In Stage II, the disease specific nature of the biomarker panel was confirmed by stratification against HC and further testing 
was performed on 59 RA patients (29 R and 30 NR) and 30 HC. Final validation of the biomarker panel was done on an independent, blinded cohort 
of 19 RA patients
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gender, RA severity (as measured by CDAI, DAS28-CRP, 
and DAS28-ESR) and MTX dosage (Additional file  1: 
Tables S3, S4). The analysis of the validation cohort was 
done using a blinded analysis, where the actual response 
calls were not known until after the identification of 
R and NR using the CCS classifier. In this independent 
cohort, we obtained a PPV of 90% (95% CI 59–98%), 
and a NPV rate of 66.7% (95% CI 42–85%), sensitivity of 
75.0% (95% CI 43–95%) and specificity of 85.7% (95% CI 
42–97%). The area under the receiver operating charac-
teristic curve (AUROC) was 0.91 (Fig.  3b). The number 
of observed and predicted patients per response cat-
egory is shown in Table 3. The strong NPV statistics for 
the blinded samples confirms the accuracy and robust 
stratification power of the CCS for non-response to MTX 
prior to treatment.
Biological and functional characterization of the genomic 
loci making up the CCS
The five genomic loci (IFNAR1, IL-21R, IL-23, IL-17A, 
and CXCL13) that make up the CCS fall within genes that 
encode for proteins involved in the immune response. 
Recently, eQTLs that overlap with enhancer elements 
have been identified in RA patients with moderate to 
Fig. 2 Clinical Data for Discovery and Testing Cohorts. Discovery cohort: (a, b). a Breakdown of disease severity by CDAI scores for the discovery 
cohort at Baseline and 6 months. b Change in CDAI scores between responders (R) and non-responders (NR) at Baseline and 6 months following 
MTX therapy. Testing cohort: (c, d). c Breakdown of disease severity by CDAI scores for the testing cohort at Baseline and 6 months. d Change in 
CDAI scores between responders (R) and non-responders (NR) at Baseline and 6 months following MTX therapy. Significant reductions in CDAI 
scores were seen between R and NR at Baseline compared to R at 6 months as well as between NR and R at 6 months (****p<0.01). For CDAI scores 
see Additional file 1: Tables S2, S3
Table 1 Coefficients of the logistic regression model 
for predicting efficacy of MTX monotherapy in baseline 
samples based on retrospective annotation at 6 months
Locus Regression coefficient Odds ratio (95% CI)
IFNAR1 2.0 7.6 (1.4–57)
IL-17A − 3.2 0.04 (0.001–0.41)
CXCL13 − 1.9 0.15 (0.02–0.69)
IL-21R 2.2 9.0 (2.1–49)
IL-23 1.4 4.2 (0.78–33)
Table 2 Observed and predicted number of R and NR 
to MTX monotherapy at 6 months using the CCS classifier
Cut off levels were chosen based on the logistic model probabilities of response 
to MTX of (approximately) > 0.70 for NR and < 0.3 for R. NR and R were defined 
as described in Additional file 1: Additional Methods
Observed response Predicted response
Non-responder Undefined Responder
Non-responder 25 1 3
Responder 3 7 20
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severe disease and inadequate response to MTX [58]. 
eQTLs are genomic loci that contribute to variation in 
expression levels of mRNAs. We mapped the genomic 
locations of the five loci in the CCS to these previously 
published eQTLs [58]. The two genomic sites that corre-
sponded to the junction of each CCS locus were mapped 
to eQTLs that were within 100, 200, 500, 1000 or 2000 
base pairs (Additional file 1: Table S9). There was enrich-
ment of eQTLs co-localized with the R-associated CCS 
loci (IFNAR1, IL-21R and IL-23). In contrast, no co-
localization was observed in the NR-associated CCS loci 
(IL-17A and CXCL13) (Fig. 4).
Discussion
To address an unmet clinical need of predicting those 
RA patients who will not respond to MTX, we analyzed 
the CCS in whole blood taken at baseline from SERA-
RA patients using a well-established method of ana-
lyzing long-range chromatin interactions [43–45]. We 
identified a 5-marker panel consisting of chromosomal 
conformations in the genomic loci of IFNAR1, IL-21R, 
IL-23, IL-17A, and CXCL13 that could identify R and NR 
to MTX with 90% sensitivity in an independent blinded 
validation cohort. This could facilitate earlier access to 
more effective therapies, thus avoiding disease progres-
sion, unnecessary exposure to potentially toxic drugs and 
diminished quality of life.
Historically, identifying predictive biomarkers for MTX 
response has been difficult [7, 12–15]. While clinical pre-
dictors of RA disease are well established [61, 62], they do 
not correlate well with response to treatment at the indi-
vidual level [13]. 35–59% of patients do not achieve clini-
cally meaningful response after starting MTX [7, 63]. In 
the SERA study, only 30% of patients responded to MTX 
monotherapy [50]. While the results presented here pro-
vide a proof-of-concept and further validation is war-
ranted, the EpiSwitch technology has several attractive 
features from the standpoint of a biomarker that can be 
used clinically [49]. First, it requires a very small amount of 
blood sample (typically 50 μl). Second, it utilizes an estab-
lished laboratory methodology and readouts (qPCR). Last, 
the turnaround time is short (~  8  h). Thus, once further 
validated, the approach described here faces low barri-
ers to clinical adoption. The CCS defined a signature that 
suggests epigenomic control over loci with a central role 
in the IL-17/IL-23 axis, with the two most informative 
long-range chromatin interactions for predicting MTX-
NR coming from IL-17A and CXCL13 loci. In agreement 
with our finding, earlier reports have suggested that IL-23, 
IFNAR1 and IL-21R are predictors of positive response 
in other diseases [64–66], while IL-17A and CXL13 are 
Fig. 3 CCS performance on randomized subsets of testing cohort and validation cohort. a Receiver operating characteristic (ROC) plots for 150 
runs of the EpiSwitch™ logistic classifier. Data for the 59 patient cohort was randomised 150 times using the WEKA sample randomisation func-
tion. This reorders the data prior to splitting in developing the training set, ensuring that the same starting point for the classifier is not used and 
allowing multiple accuracy calculations for the same data. The average area under the curve (AUC) for the 150 classifier runs was 0.90. The plot is 
the average ROC from the 150 test results. b Receiver operating characteristic (ROC) plots for the EpiSwitch™ logistic classifier run on the blinded 
validation cohort of 19 RA patients. The classifier had a sensitivity of 75.0% and specificity of 85.7% with an AUC of 0.91
Table 3 CCS classifier performance for predicting non-
response to MTX in a blinded cohort of early RA patients
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predictors of poor outcome and increased disease sever-
ity [67–71]. Several studies support the notion that IL-23/
Th17 axis drive inflammation in chronic diseases and per-
haps plays a role in the response to immunomodulating 
drugs [72–75]. Interestingly, no loci previously associated 
with MTX metabolism were implicated in our study, indi-
cating that the response to MTX was independent of how 
the drug is known to be metabolized [20, 76].
Our results are consistent with previous data reporting 
the presence of regulatory elements (i.e. eQTL) only in 
the context of inflammatory diseases and not in healthy 
controls [77].
Recently, Walsh et  al. reported that eQTL mapped 
from RA are particularly enriched in enhancer regions of 
disease related cell types such as T and B cells [58]. Pre-
vious studies have recognized that the eQTL are highly 
specific to different leucocyte subsets [78]. To explore the 
concordance of CCS data with existing genetic regulatory 
datasets, we mapped the genomic locations of the regions 
in the CCS against reported RA-specific eQTL [58]. This 
revealed a high level of co-localization of R-specific loci 
(IFNR1, IL-21R, and IL-23) to RA-specific eQTL. Nota-
bly, this level of concordance was not observed in NR 
loci (IL-17 and CXCL-13). The increased association of 
RA eQTLs with CCS regions observed in R, but not in 
NR, suggest dysregulation at the level of regulatory 3D 
genome architecture. It has been reported that eQTL are 
associated with expression of mRNA transcripts, with 
concomitant effects on protein levels [79–82]. This leaves 
open the possibility that the association of eQTL with 
CCS observed in RA-R result from phenotypic conse-
quences due to the effects of mRNA and protein expres-
sion levels. However, the impact of eQTL on protein 
levels remains poorly understood.
It is now clear that the developing immune response 
is influenced by genetic and epigenetic factors [41]. 
IFNAR1, IL-21R and IL-23 loci have been reported to play 
a key role in the pathogenesis of RA [83–85] and Th17 
cells are implicated in pathogenesis especially in the pre-
RA phase [68, 72, 73]. Whether the CCS differences we 
observed represent changes impacting the pre-RA phase 
or are acquired during the early phase of RA is at present 
unclear. We hypothesize that the different genomic archi-
tecture observed for R and NR might reflect differences in 
epigenetic host responses to early pathogenetic events, or 
particular environmental exposures. We anticipate that 
Fig. 4 Chromosome conformations in MTX responders map to RA eQTLs. Bedtools shot of CCS markers mapped within 200 bp of previously identi-
fied RA eQTLs. The overlapping CCS:eQTLs are highlighted in yellow. a The CCS regions associated with the IFNAR1 locus on chromosome 21 map 
to 6 eQTLs. b The CCS regions associated with the IL-21R locus on chromosome 16 map to 21 eQTLs. c The CCS regions associated with the IL-23 
locus on chromosome 12 map to 4 eQTLs. d The CCS regions associated with the IL-17A locus on chromosome 6 do not map to any eQTLs. e The 
CCS regions associated with the CXCL13 locus on chromosome 4 do not map to any eQTLs
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the association observed between CCS and eQTL in RA 
patients may be important to understand the heteroge-
neity of the response observed between individuals. Fur-
thermore, eQTLs present in active inflammatory diseases 
can disappear after treatment [77]. It would therefore be 
useful to determine whether the concordance of the CCS 
and eQTL observed in our study in treatment naïve RA 
responders will be linked only to the disease or change 
after MTX treatment. Moreover, it would be interesting to 
see whether the reported eQTL are linked to the disease 
state and/or the level of inflammation [68]. Our data indi-
cate that the mapping of the QTL can reveal an altered 
biological status in R and NR, however further studies are 
needed to confirm this.
The samples used in this study came from the SERA 
study, a large, multi-institutional investigational pro-
gram designed to identify predictive markers of RA 
[50]. Patients enrolled in the SERA study were carefully 
characterized for clinical phenotype (the majority of the 
patients were Caucasians, non-smokers with seropositive 
established disease), longitudinal follow-up of outcomes 
and blood samples were stored following a Standard 
Operating Procedure. This combination of clinical rigor 
and quality assurance of the inputs to the CCS are par-
ticular strengths of this study. An additional strength of 
the study is the approach that was used to generate the 
CCS. We focused on the discovery and establishment of 
a molecular signature using an approach informed by 
current biological knowledge. We evaluated a network 
of loci that had plausible pathophysiological relevance 
in RA via synovial pathogenesis studies, GWAS associa-
tion and postulated MTX pharmacogenetics [35, 54–57, 
86]. The step-wise selection of biomarkers used in this 
study, coupled with the strict separation of discovery and 
validation cohorts, was performed to prevent marker and 
model over-fitting. The robust statistical properties of 
the CCS classifier are another advantage of the approach 
presented here. Using epigenetic markers, which provide 
a binary readout (presence or absence) and are stable in 
isolated whole blood, provides high efficiency stratifica-
tion. Statistical power analysis confirmed that the sample 
size was adequate for the development and evaluation of 
the signature, a critical step in biomarker development 
and aligned with successful development of companion 
diagnostics in limited size cohorts in other indications 
[87]. A further strength to our findings and applicability 
in the clinical setting is the ability to identify this molecu-
lar signature in the whole blood by using a drop of blood.
Some of the caveats associated with our findings are the 
relatively modest sample size and the cellular heterogene-
ity present in the whole blood. While the sample size for 
the validation cohort was not as large as previous studies 
seeking to identify a biomarker for MTX non-response 
(Additional file  1: Table S1), the use of chromosome 
conformations as a readout, which can generate robust 
signatures in smaller cohorts, provide confidence in 
the approach [88, 89]. The heterogeneity of cell popula-
tions is an issue that has implications for any analysis in 
whole blood. In RA, it is known that there is significant 
heterogeneity in cell populations present in the blood 
of RA patients [90]. While outside the scope of the cur-
rent study, future studies that look at the CCS in distinct 
cell types in whole blood may shed greater light on the 
similarities and/or differences exhibited within individual 
populations. A final caveat of our study was limited in 
that it could not determine whether the observed epige-
netic marks are causal or consequential (secondary to the 
inflammatory response). Future studies looking at larger 
patient sets as well as the inclusion of individuals treated 
with other DMARDs, including biologics, are warranted.
Conclusions
The ability to identify individuals who are unlikely to 
respond to a specific therapeutic agent has the poten-
tial to not only reduce side-effects to treatments that 
will provide no benefit but also accelerate their journey 
through the treatment algorithm and thus increase like-
lihood of a positive treatment outcome. Given the high 
worldwide prevalence of RA, a stratifying signature for 
MTX response offers direct and practical benefits. The 
validated classifier described here, which is based on five 
conditional binary biomarkers detected in the blood, 
offers cost-effective detection by an established ISO-
certified industrial platform and the practicality that this 
method to stratify patients has the potential to be rou-
tinely available within clinical practice. This could be a 
first step toward personalized medicine in RA.
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